Drugs / DC-CTL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04672473 | Oct 2020 → Jul 2023 | cancer | Shenzhen University General Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02766348 | May 2016 → Dec 2017 | non-small cell lung carcinoma | Shenzhen Hornetcorn Bio-technology Company, LTD | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06524024 | Oct 2026 → Apr 2027 expected | neoplasm | Zhengzhou Revo-Gene Technology Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC-CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02766348 ↗ |
| Known as | Ag-CTL | “In this study investigators co-culture DCs cells with peptides derived from tumor specific antigen to generate antigen-specific DC-CTLs (Ag-CTL).” NCT04672473 ↗ |
| Modality | Cell therapy | “DC-CTL cells” NCT02766348 ↗ |
| Route | Subcutaneous | “subcutaneous injections of DC cells were administered” NCT06524024 ↗ |